

Client: Example Client ABC123 123 Test Drive

Salt Lake City, UT 84108 UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB 5/3/1957 **Gender:** Female

Patient Identifiers: 01234567890ABCD, 012345

Visit Number (FIN): 01234567890ABCD **Collection Date:** 00/00/0000 00:00

PD-L1 22C3 by Immunohistochemistry, with Interpretation

ARUP test code 3017615

Adequacy of Specimen

PD-L1 Client Block ID

SS24-8021 A1

PDL1 Tissue Source

RUL Lung

PDL1 TEST

TPS

PD-L1 22C3 by IHC With Tumor Proportion Score (TPS) Interpretation, Pembrolizumab (KEYTRUDA) and Cemiplimab-rwlc (LIBTAYO)

ARUP test code 3017680

Tumor Proportion Score 81-90%

PDL1 22C3 by IHC Result Exp >=50%

Controls were run and performed as expected. This result has been reviewed and approved by

H=High, L=Low, *=Abnormal, C=Critical

4848



INTERPRETIVE INFORMATION: PD-L1 22C3 IHC with Tumor Proportion Score (TPS)

PDL1 22C3 by IHC with Tumor Proportion Score Interpretation is PDL1 22C3 by IHC with Tumor Proportion Score Interpretation is an FDA-approved immunohistochemical assay using monoclonal mouse anti-PD-L1, clone 22C3 intended for use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) tissue using the Envision FLEX visualization system on Autostainer Link 48 in non-small cell lung cancer (NSCLC). PD-L1 protein expression in NSCLC is determined using the tumor proportion score (TPS), which is the percentage of viable tumor cells showing partial or complete membrane staining at any intensity

intensity.

intensity. The specimen submitted for testing must contain at least 100 viable, invasive tumor cells to be considered adequate for evaluation. This assay is indicated as an aid in identifying NSCLC patients for treatment with pembrolizumab (KEYTRUDA) and cemiplimab (LIBTAYO). For all other specimen types, results should be interpreted with caution and within the appropriate clinical context. The table below summarizes how TPS is used to assess PD-L1 expression. Please refer to the full prescribing information for tumor-specific indications and PD-L1 expression level cutoff level cutoff.

For NSCLC Patients:

TPS <1%: No PD-L1 expression

TPS >=1%: PD-L1 expression
TPS >=50%: High PD-L1 expression
Submission of slides that have been oven baked is not recommended as staining may be affected by overbaking or prolonged time between baking and staining. The use of this assay on decalcified tissues has not been validated and is not recommended. Testing on specimens fixed in any fixative other than 10 percent neutral buffered formalin has not been validated and is not recommended.

Submission of slides that have been oven baked, or specimens that are decalcified and/or fixed in any fixative other than 10 percent neutral buffered formalin are not validated and should be interpreted with caution.

Controls were run and performed as expected.

Adequacy of Specimen	Adequate
PD-L1 Client Block ID	SS24-8021 A1
PDL1 Tissue Source	RUL Lung

H=High, L=Low, *=Abnormal, C=Critical



VERIFIED/REPORTED DATES					
Procedure	Accession	Collected	Received	Verified/Reported	
Tumor Proportion Score	24-221-156549	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
PDL1 22C3 by IHC Result	24-221-156549	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
Adequacy of Specimen	24-221-156549	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
Adequacy of Specimen	24-221-156549	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
PD-L1 Client Block ID	24-221-156549	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
PD-L1 Client Block ID	24-221-156549	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
PDL1 Tissue Source	24-221-156549	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
PDL1 Tissue Source	24-221-156549	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	
PDL1 TEST	24-221-156549	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00	

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical